Healthtech funding in Q1 2024
European Healthtech startup funding raised during Q1 2024.
In Q1 2024, 124 European Healthtech companies closed 124 funding rounds and raised €930M in equity funding (excluding debt and grants), down 33.7% versus Q1 2023. Debt rounds added €24M. UK led by capital raised, and The Future of Health Grant (FoHG) program was the most active investor. Data as of 20 Nov 2026.
Equity funding
€930M
-33.7% vs Q1 2023 · excl. debt & grants · +€24M debt
Funding rounds
124
-29.9% vs Q1 2023
Companies
124
Top country
UK
Rank among sectors
#6
3.3% of sector funding
Debt financing
€24M
2.5% of total
Top-10 round share
46.2%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q1 2024 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €423M | 39 |
| Feb | €328M | 56 |
| Mar | €216M | 29 |
Top countries
by € raisedHealthtech — top countries by capital, Q1 2024 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2024 | |
|---|---|
| UK | €214M |
| Switzerland | €183M |
| Germany | €124M |
| Italy | €112M |
| France | €110M |
| Finland | €85M |
| Netherlands | €40M |
| Spain | €13M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2024 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2024 | |
|---|---|
| Other | €263M |
| Series B | €186M |
| Series C | €132M |
| Series A | €128M |
| Series D+ | €99M |
| Seed | €82M |
| Growth/Late | €32M |
| Debt | €24M |
| Grant | €14M |
| Pre-Seed | €8.1M |
Exits & M&A
10 Acquisition10 exits · €437M disclosed.
| Calypso Biotech | Acquisition | Jan 2024 | €425M |
| Apotea | Acquisition | Jan 2024 | €12M |
Top deals
largest disclosed rounds in Q1 2024| Company | Stage | Date | Amount |
|---|---|---|---|
| MMI | Series C | Feb 2024 | €102M |
| Timeline | Series D+ | Jan 2024 | €61M |
| Infinite Roots (Mushlabs) | Series B | Jan 2024 | €53M |
| Bob W | Series B | Feb 2024 | €40M |
| Phagenesis | Series D+ | Mar 2024 | €39M |
| Relation Therapeutics | Seed | Mar 2024 | €32M |
| Enterprise Therapeutics | Series B | Jan 2024 | €30M |
| Aqemia | Series A | Jan 2024 | €30M |
| Onera Health | Series C | Jan 2024 | €30M |
| Protembis | Series B | Mar 2024 | €30M |
| Hilo (Aktiia) | Other | Feb 2024 | €28M |
| icotec | Growth/Late | Jan 2024 | €28M |
| LEM Surgical | Series B | Jan 2024 | €24M |
| Spineart | Debt | Mar 2024 | €21M |
| Kinvent | Other | Jan 2024 | €16M |
Top investors
most active in Q1 2024, by deal count- The Future of Health Grant (FoHG) program8 deals
- Innovate UK3 deals
- Khosla Ventures3 deals
- Mercia Ventures3 deals
- b2venture2 deals
- BOM2 deals
- BonVenture2 deals
- Bpifrance2 deals
- Cenitz2 deals
- Credo Ventures2 deals